Personalized mRNA Cancer Vaccines Show Promising Results in Trials

Moderna and Merck's melanoma vaccine halves risk of death or relapse, with trials expanding to other cancers.

Moderna and Merck's mRNA melanoma vaccine, combined with Keytruda, reduces risk of death or cancer recurrence by 49%.
The vaccine is personalized using genetic sequencing and AI, targeting unique cancer mutations in each patient.
England's NHS launches a scheme to streamline clinical trial recruitment for cancer vaccines.
Experts see potential for mRNA vaccines to treat various cancers, including lung, pancreatic, and bladder cancers.
Late-stage trials for melanoma and lung cancer vaccines are actively enrolling participants.